Cargando…

A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia

Cancers that appear pathologically similar often respond differently to the same drug regimens. Methods to better match patients to drugs are in high demand. We demonstrate a promising approach to identify robust molecular markers for targeted treatment of acute myeloid leukemia (AML) by introducing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Su-In, Celik, Safiye, Logsdon, Benjamin A., Lundberg, Scott M., Martins, Timothy J., Oehler, Vivian G., Estey, Elihu H., Miller, Chris P., Chien, Sylvia, Dai, Jin, Saxena, Akanksha, Blau, C. Anthony, Becker, Pamela S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5752671/ https://www.ncbi.nlm.nih.gov/pubmed/29298978 http://dx.doi.org/10.1038/s41467-017-02465-5

Ejemplares similares

Comparison between measurable residual disease relapse and morphologic relapse in acute myeloid leukemia and high-grade myeloid neoplasms
por: Shih, Lauren, et al.
Publicado: (2023)

Phase 1/2 Trial of CLAG-M with Dose-Escalated Mitoxantrone in Combination with Fractionated-Dose Gemtuzumab Ozogamicin for Newly Diagnosed Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
por: Godwin, Colin D., et al.
Publicado: (2022)

Impact of region of diagnosis, ethnicity, age, and gender on survival in acute myeloid leukemia (AML)
por: Acharya, Utkarsh H., et al.
Publicado: (2018)

Therapeutic Options for Patients who are not Eligible for Intensive Chemotherapy
por: Estey, Elihu
Publicado: (2013)

Effect of ECOG performance status on outcomes in patients with acute myeloid leukemia and other high-grade myeloid neoplasms
por: Paras, Gabrielle, et al.
Publicado: (2022)

Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia
por: Cortes, Jorge E., et al.
Publicado: (2020)

Improved outcomes with “7+3” induction chemotherapy for acute myeloid leukemia over the past four decades: analysis of SWOG trial data
por: Othus, Megan, et al.
Publicado: (2022)

Effect of Measurable (“Minimal”) Residual Disease (MRD) Information on Prediction of Relapse and Survival in Adult Acute Myeloid Leukemia
por: Othus, Megan, et al.
Publicado: (2016)

Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality
por: Sorror, Mohamed L., et al.
Publicado: (2017)

Prognostic impact of secondary versus de novo ontogeny in acute myeloid leukemia is accounted for by the European LeukemiaNet 2022 risk classification
por: Hochman, Michael J., et al.
Publicado: (2023)

Mitoxantrone, Etoposide, and Cytarabine (MEC) Following Epigenetic Priming with Decitabine in Adults with Relapsed/Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms: A Phase 1/2 Study
por: Halpern, Anna B., et al.
Publicado: (2017)

Effect of Genetic Profiling on Prediction of Therapeutic Resistance and Survival in Adult Acute Myeloid Leukemia
por: Walter, Roland B., et al.
Publicado: (2015)

Pre- and Post-Transplant Quantification of Measurable (“Minimal”) Residual Disease via Multiparameter Flow Cytometry in Adult Acute Myeloid Leukemia
por: Zhou, Yi, et al.
Publicado: (2016)

Precision therapy for acute myeloid leukemia
por: Yang, Xue, et al.
Publicado: (2018)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility
por: Percival, Mary-Elizabeth M., et al.
Publicado: (2020)

New drug approvals in acute myeloid leukemia: what’s the best end point?
por: Estey, E, et al.
Publicado: (2015)

Editorial: Precision medicine for acute myeloid leukemia
por: Marconi, Giovanni, et al.
Publicado: (2023)

Proteomic Characterization of Acute Myeloid Leukemia for Precision Medicine
por: Casado, Pedro, et al.
Publicado: (2023)

Mesenchymal stromal cells derived from acute myeloid leukemia bone marrow exhibit aberrant cytogenetics and cytokine elaboration
por: Huang, J C, et al.
Publicado: (2015)

Dependence of Acute Myeloid Leukemia on Adhesion within the Bone Marrow Microenvironment
por: Becker, Pamela S.
Publicado: (2012)

Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants
por: Cicconi, Laura, et al.
Publicado: (2021)

Explainable artificial intelligence for precision medicine in acute myeloid leukemia
por: Gimeno, Marian, et al.
Publicado: (2022)

Combined Population Dynamics and Entropy Modelling Supports Patient Stratification in Chronic Myeloid Leukemia
por: Brehme, Marc, et al.
Publicado: (2016)

Regimen‐intensity per count‐recovery and hospitalization index: A new tool to assign regimen intensity for AML
por: Sorror, Mohamed L., et al.
Publicado: (2020)

MicroRNA-150 Expression Induces Myeloid Differentiation of Human Acute Leukemia Cells and Normal Hematopoietic Progenitors
por: Morris, Valerie A., et al.
Publicado: (2013)

Cytogenetics’ impact on the prognosis of acute myeloid leukemia
por: Gupta, Monika, et al.
Publicado: (2019)

Regulation of myeloid leukemia by the cell fate determinant Musashi
por: Ito, Takahiro, et al.
Publicado: (2010)

Phase 1/2 Trial of GCLAM with Dose-Escalated Mitoxantrone for Newly Diagnosed AML or Other High-Grade Myeloid Neoplasms
por: Halpern, Anna B., et al.
Publicado: (2018)

A precision medicine classification for treatment of acute myeloid leukemia in older patients
por: Mims, Alice S., et al.
Publicado: (2021)

Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia
por: Malani, Disha, et al.
Publicado: (2022)

Extracting a low-dimensional description of multiple gene expression datasets reveals a potential driver for tumor-associated stroma in ovarian cancer
por: Celik, Safiye, et al.
Publicado: (2016)

Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia
por: Berenstein, Rimma, et al.
Publicado: (2015)

Prediction of CR following a second course of ‘7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course
por: Othus, M, et al.
Publicado: (2016)

BIG DATA ANALYTICS AND PRECISION ANIMAL AGRICULTURE SYMPOSIUM: Machine learning and data mining advance predictive big data analysis in precision animal agriculture
por: Morota, Gota, et al.
Publicado: (2018)

Big data hurdles in precision medicine and precision public health
por: Prosperi, Mattia, et al.
Publicado: (2018)

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
por: Hirsch, Pierre, et al.
Publicado: (2017)

From Big Data to Precision Medicine
por: Hulsen, Tim, et al.
Publicado: (2019)

Sparse expression bases in cancer reveal tumor drivers
por: Logsdon, Benjamin A., et al.
Publicado: (2015)

Treatment of Cancer Gene Changes in Chronic Myeloid Leukemia by Big Data Analysis Platform-Based Dasatinib
por: Song, Linlin, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5ac6kivhq7fnn9amj3bpnt48hq